Silence Therapeutics plc (OTCMKTS:SLNCF) Short Interest Update

Silence Therapeutics plc (OTCMKTS:SLNCF) was the recipient of a large increase in short interest in the month of August. As of August 14th, there was short interest totaling 520 shares, an increase of ∞ from the July 30th total of 0 shares. Based on an average daily volume of 415 shares, the days-to-cover ratio is currently 1.3 days.

Silence Therapeutics Stock Performance

Shares of OTCMKTS SLNCF remained flat at $4.00 during trading hours on Monday. The company has a 50-day moving average of $2.66 and a 200 day moving average of $2.11. Silence Therapeutics has a one year low of $1.06 and a one year high of $5.99.

About Silence Therapeutics

Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.

The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.